Search Results - "Di Bernardo, Matteo"

  • Showing 1 - 17 results of 17
Refine Results
  1. 1

    easyFulcrum: An R package to process and analyze ecological sampling data generated using the Fulcrum mobile application by Di Bernardo, Matteo, Crombie, Timothy A, Cook, Daniel E, Andersen, Erik C

    Published in PloS one (06-10-2021)
    “…Large-scale ecological sampling can be difficult and costly, especially for organisms that are too small to be easily identified in a natural environment by…”
    Get full text
    Journal Article
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7

    Clinicopathologic Profile and Psychosocial Experiences of Nigerian Breast Cancer Survivors by Wuraola, Funmilola Olanike, Olasehinde, Olalekan, Di Bernardo, Matteo, Aderounmu, Adewale Abdulwasiu, Adisa, Adewale Oluseye, Omoyiola, Oluwatosin Zaniab, Omisore, Adeleye Dorcas, Kingham, Thomas Peter, Mango, Victoria, Alatise, Olusegun Isaac

    Published in JCO global oncology (01-09-2023)
    “…Breast cancer survivors are a distinct category of patients with unique characteristics and needs. The population of survivors is expected to increase, given…”
    Get full text
    Journal Article
  8. 8

    Breast cancer in elderly patients: a clinicopathological review of a Nigerian database by Wuraola, Funmilola Olanike, Olasehinde, Olalekan, Di Bernardo, Matteo, Akinkuolie, Akinbolaji A, Adisa, Adewale O, Aderounmu, Adewale A, Mohammed, Tajudeen O, Omoyiola, Oluwatosin Z, Kingham, Thomas P, Alatise, Olusegun I

    Published in Ecancermedicalscience (2022)
    “…Breast cancer in the elderly population has not been evaluated in the Nigerian context. With the rising incidence of breast cancer and the changing…”
    Get full text
    Journal Article
  9. 9

    Abstract 2: Addressing treatment resistance in models of lethal prostate cancer by Vasciaveo, Alessandro, de Almeida, Francisca Nunes, Zou, Min, Bernardo, Matteo Di, Califano, Andrea, Abate-Shen, Cory

    Published in Cancer research (Chicago, Ill.) (01-07-2021)
    “…Abstract Prostate cancer (PC) is the malignancy with the highest incidence worldwide in males. Although localized disease can be effectively treated and…”
    Get full text
    Journal Article
  10. 10

    Abstract LB247: A forward genetic screen to identify drivers of neuroendocrine prostate cancer by de Almeida, Francisca Nunes, Vasciaveo, Alessandro, Zou, Min, Di Bernardo, Matteo, Califano, Andrea, Abate-Shen, Cory

    Published in Cancer research (Chicago, Ill.) (01-07-2021)
    “…Abstract Neuroendocrine prostate cancer (NEPC) is a deadly variant of prostate cancer for which no cure is yet available. Up to 20 percent of the patients with…”
    Get full text
    Journal Article
  11. 11
  12. 12
  13. 13

    Abstract 78: The Clinicopathological and Psychosocial Profile of A Cohort of Nigerian Breast Cancer Survivors by Wuraola, Funmiola, Olasehinde, Olalekan, Bernardo, Matteo Di, Mango, Victoria, Kingham, T Peter, Adisa, Adewale, Alatise, Olusegun

    “…Abstract Purpose: Breast cancer survivors are a distinct category of patients with peculiar characteristics and needs. The population of survivors is expected…”
    Get full text
    Journal Article
  14. 14

    Abstract 1116: Identifying neuroendocrine prostate cancer drivers using in vivo forward genetics by Vasciaveo, Alessandro, Nunes De Almeida, Francisca, Zou, Min, Di Bernardo, Matteo, Califano, Andrea, Abate-Shen, Cory

    Published in Cancer research (Chicago, Ill.) (04-04-2023)
    “…Abstract Prostate cancer (PC) is the malignancy with the highest incidence worldwide in males. Although localized disease can be effectively treated and…”
    Get full text
    Journal Article
  15. 15

    Abstract 5773: A forward genetic screen identifies SIRT1 as a driver of neuroendocrine prostate cancer by de Almeida, Francisca Nunes, Vasciaveo, Alessandro, Zou, Min, Bernardo, Matteo Di, Califano, Andrea, Abate-Shen, Cory

    Published in Cancer research (Chicago, Ill.) (04-04-2023)
    “…Abstract Neuroendocrine prostate cancer (NEPC) is a deadly variant of prostate cancer for which no cure is yet available. Up to 20 percent of the patients with…”
    Get full text
    Journal Article
  16. 16
  17. 17